

Thermo Fisher Scientific opens flagship bioprocess design centre in US

April 29, 2026 | News

To accelerate the delivery of life-changing therapies



Thermo Fisher Scientific has announced the opening of its flagship US Bioprocess Design Center (BDC) at the company's Plainville, Mass., site, expanding the facility to support customers in developing and scaling biologics.

The new centre brings together advanced bioproduction capabilities and hands-on collaboration to help customers accelerate process development and bring transformative therapies to patients faster. The facility demonstrates Thermo Fisher's continued commitment to empowering customers as a trusted innovation partner.

The BDC features 4,000 square feet of laboratory and training space to support customers in developing biologics, including vaccines and cell and gene therapies. Customers will experience Thermo Fisher's complete, end-to-end bioproduction workflow of integrated, scalable solutions – including media, cell line development, single-use systems, chromatography, filtration, purification and analytics – that can unlock productivity gains and reduce time to market.

The strategic addition of the BDC to Thermo Fisher's 290,000-square-foot Plainville facility introduces bioproduction capabilities that complement its existing integrated sterile fill-finish and viral vector services and demonstrates the company's comprehensive expertise across the drug development continuum. Located in the greater Massachusetts life science ecosystem, the center is well-positioned for customer collaboration across the US, with a shared goal of bringing innovative treatments and hope to patients.